Infinity Pharmaceuticals to Present at UBS Conference
September 12, 2011 08:00 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Sept. 12, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) will be presenting at UBS Global Life Sciences Conference on Monday, September 19, 2011 at 2:00 p.m....
Infinity Pharmaceuticals to Present at Two Upcoming Conferences
August 30, 2011 16:00 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Aug. 30, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) will be presenting at the Stifel Nicolaus Healthcare Conference on Wednesday, September 7, 2011 at...
Infinity Reports Second Quarter 2011 Financial Results
August 09, 2011 16:00 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Aug. 9, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today highlighted its recent clinical and business progress and announced its second quarter 2011...
Infinity Announces the Date of Its Second Quarter 2011 Financial Results Conference Call and Webcast
August 02, 2011 08:00 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Aug. 2, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) will host a conference call on Tuesday, August 9, 2011 at 4:30 p.m. ET. During the call, management will...
Photo Release -- Biopharmaceutical Company Seeks New Sources of Corn Lily
June 22, 2011 10:00 ET
|
Infinity Pharmaceuticals, Inc.
SALT LAKE CITY and BOISE, Idaho, June 22, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc., a Massachusetts-based biopharmaceutical company, is seeking new sources of a plant commonly known as...
Infinity Expands Clinical Development Program for IPI-926, an Oral Smoothened Antagonist Targeting the Hedgehog Pathway
June 22, 2011 08:00 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., June 22, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that it is expanding its clinical development program for IPI-926, a novel, oral small...
Infinity Presents Data on Retaspimycin Hydrochloride, a Novel Hsp90 Inhibitor, in Non-Small Cell Lung Cancer at ASCO Meeting
June 06, 2011 15:00 ET
|
Infinity Pharmaceuticals, Inc.
CHICAGO, June 6, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced encouraging results from a Phase 1b trial of retaspimycin hydrochloride (HCl) (also known as...
Infinity Reports Results From Phase 1b Clinical Trial of IPI-926, an Oral Smoothened Antagonist, in Pancreatic Cancer at ASCO Meeting
June 04, 2011 09:00 ET
|
Infinity Pharmaceuticals, Inc.
CHICAGO, June 4, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced encouraging results from the Phase 1b portion of an ongoing Phase 1b/2 clinical trial of IPI-926...
Infinity to Highlight Clinical Progress and Review Abstracts to be Presented at ASCO Annual Meeting
June 01, 2011 06:00 ET
|
Infinity Pharmaceuticals, Inc.
— Company to Host Webcast and Conference Call Today at 8:30 a.m. ET with Dr. Gregory Riely, Principal Investigator for Ongoing Phase 2 Trial of Retaspimycin HCl, a Novel...
Infinity Pharmaceuticals to Present at Jefferies Conference
May 31, 2011 08:00 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 31, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) will be presenting at Jefferies Global Healthcare Conference on Wednesday, June 8, 2011 at 9:30 a.m. ET...